Advertisement

Topics

Adding Palifosfamide in Extensive-Stage SCLC Did Not Increase Survival

10:05 EDT 19 Jun 2017 | Cancer Networks

Adding palifosfamide to carboplatin and etoposide failed to improve survival over the latter two agents alone in patients with extensive-stage small-cell lung cancer.

Original Article: Adding Palifosfamide in Extensive-Stage SCLC Did Not Increase Survival

NEXT ARTICLE

More From BioPortfolio on "Adding Palifosfamide in Extensive-Stage SCLC Did Not Increase Survival"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...